FDA approves Botox to treat overactive bladder
Jan 18 (Reuters) - U.S. health regulators approved Allergan Inc's blockbuster wrinkle smoother Botox to treat adults with overactive bladders who do not respond adequately to other therapies.
The U.S. Food and Drug Administration said Botox can be injected into the bladder muscle, allowing the muscle to relax and improving bladder capacity.
The treatment can be repeated when the effect wears off, but with a gap of at least 12 weeks between treatments, the FDA said in a statement on its website. ()
- U.S.' Kerry voices 'regret' to India over diplomat case |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Mega Millions winners in Georgia, California to split $648 million |
- Medical bills underlie 60 percent of U.S. bankrupts: study